ArticleFrontiers in pharmacology2022

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data.

Quanfeng Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.